A carregar...
Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates
Human epidermal growth factor receptor 2 (HER2)-targeted therapies have revolutionized the treatment of HER2-positive breast cancer, both in the metastatic and early stage settings. While trastuzumab and lapatinib had been the mainstays of treatment in combination with chemotherapy, innate and acqui...
Na minha lista:
| Publicado no: | Ann Transl Med |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AME Publishing Company
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4260046/ https://ncbi.nlm.nih.gov/pubmed/25568875 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2305-5839.2014.08.13 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|